Marketing: Page 5
-
Courtesy of Roche
Roche writes off $3B on lower sales forecasts for gene therapies, cancer drugs
Among the drugs Roche recorded impairment charges on are four gene therapies acquired in the company's 2019 deal for Spark Therapeutics.
By Jonathan Gardner • Feb. 3, 2023 -
Lilly reports fast sales for new diabetes drug
Still, fourth quarter sales for Mounjaro were slightly below high Wall Street forecasts and didn’t offset falling revenue from Lilly’s COVID-19 antibodies.
By Jonathan Gardner • Updated Feb. 2, 2023 -
Explore the Trendline➔
Brian Tucker / BioPharma Dive
TrendlineCommercialization
New drugs for obesity and Alzheimer’s look set to become blockbusters, reshaping pharma marketing strategies just as many current top-sellers near looming patent cliffs.
By BioPharma Dive staff -
Bill Oxford via Getty Images
Court rules for drugmakers in 340B fight over contract pharmacies
The decision is a win for Sanofi, Novo Nordisk and AstraZeneca. The drugmakers sued HHS after regulators ordered them to stop restricting sales of 340B drugs to contract pharmacies.
By Rebecca Pifer • Jan. 31, 2023 -
Amgen Inc.
Humira biosimilars arrive in the US, as Amgen launches first copycat to AbbVie’s blockbuster drug
The world’s best-selling drug will face pricing pressure as rivals try to steal share from AbbVie’s $20 billion-a-year flagship product in the U.S.
By Jonathan Gardner • Jan. 31, 2023 -
Jonathan Gardner / BioPharma Dive
BeiGene wins expanded approval for leukemia drug, intensifying battle with AbbVie, AstraZeneca
The drugmaker hopes Brukinsa’s survival data will help its drug compete with Imbruvica and Calquence.
By Jonathan Gardner • Jan. 20, 2023 -
Ridofranz via Getty Images
Sponsored by Kwello by Acceleration PointHow social listening can boost your Medical Affairs strategy for 2023 and beyond
Digital innovation continues to transform the healthcare and biopharmaceutical landscape, and as it does, the role of Medical Affairs is changing.
Jan. 17, 2023 -
Win McNamee via Getty Images
Looking past Humira, AbbVie boosts sales forecasts for successor drugs
Competition to Humira will weigh on AbbVie, but the pharma has laid out ambitious expectations for fast growth from its medicines Skyrizi and Rinvoq.
By Jonathan Gardner • Jan. 11, 2023 -
Pharma companies boost drug prices to start year, but hikes lag inflation
Analysts noted hundreds of list price increases, including dozens by Pfizer. Many checked in around 5%, roughly in line with hikes taken in recent years.
By Jonathan Gardner • Jan. 3, 2023 -
artJazz via Getty Images
European regulators back hemophilia gene therapy
The EMA’s drug review committee recommended five new drugs be approved in Europe during its December meeting, including CSL’s Hemgenix, AstraZeneca’s Imjudo and Amicus’ Pombiliti.
By Jacob Bell • Dec. 16, 2022 -
Photo: Will Warasila for Industry Dive
Deep Dive // ALS drug developmentFor ALS patients, doctors, a new medicine reignites concerns about healthcare access
Relyvrio, a drug developed by Amylyx Pharmaceuticals, is in high demand in ALS clinics across the U.S. Though some patients are already getting it, insurance coverage and out-of-pocket costs remain a source of anxiety.
By Jacob Bell , Shaun Lucas • Dec. 15, 2022 -
Permission granted by Bluebird bio
Gene therapy approval won, Bluebird takes on next challenge: selling it
The biotech is still waiting to treat its first commercial patient with Zynteglo, but says it has not seen insurers deny coverage for the beta thalassemia drug.
By Ned Pagliarulo • Dec. 12, 2022 -
Hinterhaus Productions via Getty Images
Sponsored by First Republic BankLife science investment outlook: thinking beyond the pandemic
Learn about the investment landscape for life science companies, heading into 2023.
Dec. 12, 2022 -
Ivan-Balvan via Getty Images
Esperion, without data, says cholesterol pill lowered heart risk in study
The large cardiovascular outcomes trial is a major test for Esperion, which has struggled to sell its drug Nexletol since winning U.S. approval in 2020.
By Ned Pagliarulo • Dec. 7, 2022 -
Courtesy of GSK
GSK to pull blood cancer drug from US market after study failure
The British drugmaker has begun the process of withdrawing its multiple myeloma treatment Blenrep following a request from the FDA.
By Ned Pagliarulo • Nov. 22, 2022 -
Drazen_ via Getty Images
Sponsored by Ogilvy HealthHow brands can tap into wellness – lessons from influencers
Our latest research uncovers new insights on how brands can truly close the wellness gap and grow within their industry sectors.
By Marion McDonald, Managing Director, Ogilvy Health • Nov. 21, 2022 -
Jacob Bell
For ImmunoGen, persistence pays off as FDA clears ovarian cancer drug
The approval makes Elahere the first wholly owned medicine the biotech has brought to market in its lengthy history.
By Jonathan Gardner • Nov. 15, 2022 -
Permission granted by Pear Therapeutics
Pear Therapeutics undergoes another round of layoffs, cutting 22% of staff
The digital therapeutics company said the reductions will extend its cash runway and curb its reliance on financing.
By Elise Reuter • Nov. 15, 2022 -
Courtesy of GSK Flickr page
Under FDA pressure, GSK limits use of ovarian cancer drug
The drugmaker’s decision is the latest fallout from safety concerns that have emerged in testing of so-called PARP inhibitors, resulting in withdrawals by Merck & Co., AstraZeneca and Clovis Oncology.
By Jonathan Gardner • Nov. 11, 2022 -
Courtesy of EQRx
EQRx redraws ‘radical’ drug pricing plans for first two drugs
The buzzy startup, which planned to undercut big pharma on price, also dropped plans to seek U.S. approval in lung cancer of an immunotherapy competitor to Keytruda.
By Jonathan Gardner • Nov. 10, 2022 -
Novo Nordisk
Novo obesity drug sales lag as manufacturing problems persist
Manufacturing problems continue to weigh on Novo’s Wegovy launch as competition looms from Eli Lilly’s fast-selling diabetes medicine Mounjaro.
By Jonathan Gardner • Nov. 2, 2022 -
Lilly sales of new diabetes drug accelerate on rising patient demand
Company executives highlighted the “viral nature” of demand for Mounjaro, which was approved in May for diabetes and has also shown a strong weight-loss benefit in clinical testing.
By Ned Pagliarulo • Nov. 1, 2022 -
Gilead Sciences Inc. / Kite Pharma
Gilead, fueled by latest approval, sees CAR-T sales take off
After a slow start, Gilead’s CAR-T business is growing fast, enabling it to pull ahead of rival cell therapy developers like Bristol Myers Squibb and J&J.
By Jacob Bell • Oct. 28, 2022 -
Novartis
Novartis sales of Zolgensma gene therapy slow as market shifts
Treatment is now mostly of infants newly diagnosed with spinal muscular atrophy, as many of those previously eligible either already received Zolgensma or other drugs from Biogen and Roche.
By Ned Pagliarulo • Oct. 25, 2022 -
Finbarr Webster via Getty Images
Pfizer planning steep price hike for COVID-19 vaccine
The company is considering charging as much as between $110 and $130 per dose — roughly four times the vaccine’s current price — once sales transition to the private market.
By Ned Pagliarulo • Oct. 21, 2022 -
Alarmy.com/Yuri Arcurs
Sponsored by First Republic BankBuilding the dream team: How life science startups can attract top talent
Learn how to attract and retain top talent, in an ultra-competitive labor market.
By Nishta Rao, Managing Director, Life Science, First Republic Bank • Oct. 17, 2022
Previous
